https://www.selleckchem.com/pr....oducts/pf-06463922.h
The 5-aminosalicylates, especially mesalazine, are the first option in the treatment of mild-to-moderate ulcerative colitis (UC). High rates of remission induction and maintenance have been observed with the new multimatrix (MMX) mesalazine formulation, mainly in patients with distal disease. Our aim was to describe the real-world experience with MMX mesalazine in patients with UC at two tertiary care centers. A retrospective cohort study was conducted that included 142 patients with confirmed UC diagnosis, analyzed in three study g
Like
Comment
Share
